>
E-Therapeutics logo

ETX - E-Therapeutics Share Price

29.4p 0.1  0.5%

Last Trade - 9:37am

Sector
Healthcare
Size
Small Cap
Market Cap £123.1m
Enterprise Value £108.1m
Revenue £305k
Position in Universe 992nd / 1821
Bullish
Bearish
Unlock ETX Revenue
Momentum
Relative Strength (%)
1m +33.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.044 0.46 0.20 0.20
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 July 2020,e-Therapeutics plc revenues decreased 80% to £37K. Net lossincreased 82% to £2.4M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsAdministrative Expenses increase from £599K to £1.5M(expense), Research and Development expenditure increase of8% to £1.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ETX
Graphical History

Revenue

ETX Revenue Unlock ETX Revenue

Net Income

ETX Net Income Unlock ETX Revenue

Normalised EPS

ETX Normalised EPS Unlock ETX Revenue

PE Ratio Range

ETX PE Ratio Range Unlock ETX Revenue

Dividend Yield Range

ETX Dividend Yield Range Unlock ETX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ETX EPS Forecasts Unlock ETX Revenue
Profile Summary

e-Therapeutics Plc is a United Kingdom-based company, which provides computer-based drug discovery platform. The Company uses its Network-Driven Drug Discovery (NDD) platform to develop intellectual property protected and pre-clinical drug discovery programs. The Company utilizes its biological proficiency and computer-based platform to create and analyze network models of disease processes to identify patterns of proteins. NDD enables network analysis, data mining, machine learning, artificial intelligence and optimization to match drug-like small molecules to its networks based on their potential bioactivity.

Directors
Last Annual January 31st, 2020
Last Interim July 31st, 2020
Incorporated October 15, 2001
Public Since November 28, 2007
No. of Shareholders: n/a
No. of Employees: 16
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 420,773,546
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ETX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ETX
Upcoming Events for ETX
Thursday 13th May, 2021
Full Year 2021 E-Therapeutics PLC Earnings Release
Wednesday 2nd June, 2021 Estimate
E-Therapeutics PLC Annual Shareholders Meeting
Frequently Asked Questions for E-Therapeutics
What is the E-Therapeutics share price?

As of 9:37am, shares in E-Therapeutics are trading at 29.4p, giving the company a market capitalisation of £123.1m. This share price information is delayed by 15 minutes.

How has the E-Therapeutics share price performed this year?

Shares in E-Therapeutics are currently trading at 29.4p and the price has moved by 0.141k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the E-Therapeutics price has moved by 95.84% over the past year.

What are the analyst and broker recommendations for E-Therapeutics?

Of the analysts with advisory recommendations for E-Therapeutics, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for E-Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will E-Therapeutics next release its financial results?

E-Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-07-31
What is the E-Therapeutics dividend yield?

E-Therapeutics does not currently pay a dividend.

Does E-Therapeutics pay a dividend?

E-Therapeutics does not currently pay a dividend.

When does E-Therapeutics next pay dividends?

E-Therapeutics does not currently pay a dividend.

How do I buy E-Therapeutics shares?

To buy shares in E-Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of E-Therapeutics?

Shares in E-Therapeutics are currently trading at 29.4p, giving the company a market capitalisation of £123.1m.

Where are E-Therapeutics shares listed? Where are E-Therapeutics shares listed?

Here are the trading details for E-Therapeutics:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ETX
What kind of share is E-Therapeutics?

Based on an overall assessment of its quality, value and momentum, E-Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a E-Therapeutics share price forecast 2021?

Shares in E-Therapeutics are currently priced at 29.4p. At that level they are trading at 45.3% premium to the analyst consensus target price of 20.23.

Analysts covering E-Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.0126 for the next financial year.

How can I tell whether the E-Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like E-Therapeutics. Over the past six months, the relative strength of its shares against the market has been 95.61%. At the current price of 29.4p, shares in E-Therapeutics are trading at 63.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the E-Therapeutics PE Ratio?

We were not able to find PE ratio data for E-Therapeutics.

Who are the key directors of E-Therapeutics?

E-Therapeutics's management team is headed by:

Trevor Jones - NEC
Ali Mortazavi - CEO
Michael Bretherton - NED
Karl Keegan - CFO
Who are the major shareholders of E-Therapeutics?

Here are the top five shareholders of E-Therapeutics based on the size of their shareholding:

Griffiths (Richard Ian) Individual Investor
Percentage owned: 22.53% (94.8m shares)
Mortazavi (Ali) Individual Investor
Percentage owned: 12.04% (50.7m shares)
Quested (Robert) Individual Investor
Percentage owned: 11.76% (49.5m shares)
Trillian, Ltd. Corporation
Percentage owned: 6.73% (28.3m shares)
Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 4.98% (21.0m shares)
Similar to ETX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.